Ignite Creation Date:
2024-05-06 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631836
Status:
UNKNOWN
Last Update Posted:
2018-08-17
First Post:
2018-08-13
Brief Title:
Phase I Study of Monoclonal Antibondy GS 5745 an Matix Metalloproteinase 9 MMP9 Mab Inhibitor in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Sponsor:
Organization:
Assistance Publique Hopitaux De Marseille
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
34
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: